lot late-stag pipelin read horizon await new ceo
invest summari reiter overweight rate price
target gilead report in-lin vs consensu top bottom
line adjust inventori cog total product revenu
vs bloomberg consensu compani also note favor
impact inventori build payer mix bottom line earn
line vs back impact
cog due excess harvoni inventori stock indic hour
think busi stabl expect notabl compani releas
finch galapago glpg ow cover merl studi
filgotinib although timelin remain track
guidanc higher consensu expect total product
revenu guidanc vs consensu increas
product revenu previou estim increas
hiv estim reflect expect benefit us japan hiv
sale lower hcv estim reflect eros line
guidanc remain low end guidanc
think remain vigil seek opportun
compani note hard find late-stag deal fit target profil
one key overhang remain investor better understand
new ceo may long take effect chang think
move forward partnership pipelin asset would expect new
ceo like move pace current busi would like see
compani late-stag deal drive greater top bottom line growth
next year two appreci find opportun easi
relat pipelin nash remain key moment
compani selonsertib think investor expect remain low success
upcom stellar studi result think risk/reward favor
either studi hit think real credit assign
blockbust nash remain somewhat cautiou mostli signal
base rel small studi think biolog rational
data encourag filgotinib think compani continu
sound confid convers us regul path
forward speak compani think flexibl
manta studi could includ data far also note
enrol pick chang made
disclosur section may found page
use probability-adjust dcf analysi valu gilead share assum discount rate
model revenu assum termin valu
risk overweight rate price target includ hiv gener competit risk
particularli gsk cover brand side slower less success biktarvi
launch expect slow car-t sale current competit emerg next-gen
car-t failur cell therapi modal grow drive stabil growth long term
late-stag pipelin failur particularli nash franchis filgotinib trial
clinic regulatori commerci risk prevent franchis contribut
million except ep
hiv hbv
royalti contract revenu
provis incom tax
net incom gilead non-
net incom non-control interest
net loss non-control interest
growth ep dilut
net incom
non- reconcili
million except ep
acquisit relat amort intang
acquisition-rel amort inventori mark-up
acquisit relat amort intang
non- incom expens
incom tax effect non-gaap adjust
tax non-gaaap adjust
cog total
 total
sg total
issuanc stock share buyback
chang work capit
present valu flow
npv
npv termin valu
tv
million except ep
growth total hcv
growth total hiv
japan broken
japan broken
epclusa japan
japan
million except ep
million except ep
gilead global biopharmaceut compani major base busi revenu base infecti diseas
pipelin evolv inflamm oncolog nash compani headquart foster citi california
